Immunotherapy in allogeneic hematopoietic stem cell transplantation - not just a case for effector cells

The concept that in allogeneic hematopoietic stem cell transplantation (alloHSCT) the immune system plays a prominent role in the control of leukemic disease is supported by the clinical observation that immunological effector mechanisms contribute to the elimination of leukemic blasts. The failure...

Full description

Saved in:
Bibliographic Details
Published inBone marrow transplantation (Basingstoke) Vol. 35; no. S1; pp. S59 - S64
Main Authors Troeger, A, Meisel, R, Moritz, T, Dilloo, D
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.03.2005
Subjects
Animals
Anticancer properties
Antigens
Bone marrow
Care and treatment
Cytotoxicity
Dendritic Cells - immunology
Dendritic Cells - transplantation
Diagnosis
Effector cells
Graft vs Host Disease - immunology
Graft vs Host Disease - prevention & control
Graft vs Leukemia Effect - immunology
Health aspects
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Humans
Immune response
Immune system
Immunology
Immunomodulation
Immunotherapy
Immunotherapy, Adoptive - methods
Leukemia
Leukemia - immunology
Leukemia - therapy
Mesenchymal Stem Cell Transplantation
Mesenchymal stem cells
Mesenchymal Stromal Cells - immunology
Mesenchyme
Remission
Risk factors
Stem cell transplantation
Stem cells
Transplantation
Transplantation, Autologous
Transplantation, Homologous
Vaccination
Germany
Online AccessGet full text

Cover

More Information
Summary:The concept that in allogeneic hematopoietic stem cell transplantation (alloHSCT) the immune system plays a prominent role in the control of leukemic disease is supported by the clinical observation that immunological effector mechanisms contribute to the elimination of leukemic blasts. The failure to induce prolonged remission after alloHSCT has led to resurgent interest in complementing concepts of immune modulation to improve the antileukemic reponse. While the general focus has been placed on manipulation of cytotoxic effector cell populations, we will explore the dual role of leukemia cells as both antigen-presenting and target cells and describe various vaccination strategies to facilitate a protective antileukemic immune response in this setting. In addition, we will introduce mesenchymal stem cells (MSC) as another cell population recently recognized for their immunomodulatory properties. The potential benefits and hazards of MSC-cotransplantation in alloHSCT with regard to the graft versus leukemia (GvL) and the graft versus host (GvH) response will be discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-2
ObjectType-Feature-1
content type line 23
SourceType-Conference Papers & Proceedings-1
ObjectType-Conference-3
SourceType-Scholarly Journals-1
ObjectType-Feature-3
ObjectType-Review-1
ISSN:0268-3369
1476-5365
DOI:10.1038/sj.bmt.1704849